Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)
Yifan Feng(Sun Yat-sen University), Minhang Xin(Zhejiang University), Chengyuan Liang(Institute of Botany), Weiming Duan(Xi'an Jiaotong University), Xiaochuan Cu
Cited by 59
Related Papers
Small molecule selenium-containing compounds: Recent development and therapeutic applications
|European Journal of Medicinal Chemistry|2021|233
Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: Ganoderic acids A, C2, D, F, DM, X and Y
|European Journal of Medicinal Chemistry|2019|192
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
|European Journal of Medicinal Chemistry|2018|168
Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
|European Journal of Medicinal Chemistry|2020|120
Strategies to target the Hedgehog signaling pathway for cancer therapy
|Medicinal Research Reviews|2018|108